Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

摘要: Objective. To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients rheumatoid arthritis (RA). Methods. This retrospective analysis used data from RADIUS 1, a 5-year observational registry RA, to determine time first- second-course etanercept, infliximab, adalimumab. First-course was defined as first exposure anti-TNF therapy, after the discontinuation. Kaplan-Meier survival assess persistence, log-rank tests were compare therapies, Cox proportional hazards models potential treatment Results. included 2418 patients. Mean rates similar among treatments [first-course: 51%; 48%; adalimumab, 48% (followup 54 weeks for etanercept infliximab 42 adalimumab); second-course: 56%, 50%, 46%, respectively 36 30 adalimumab)]. Discontinuations first-course due ineffectiveness (etanercept, 19%; 20%) discontinuations adverse events significantly (p = 0.0006) lower than 14%; 22%; 17%). Predictors univariable or increased comorbidities (etanercept), female sex (infliximab), Clinical Disease Activity Index > 22 Stanford Health Assessment Questionnaire score 0.5 (adalimumab). Conclusion. In this population, therapies. compared infliximab.